Navigation Links
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Date:8/6/2010

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference.  The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET.  The presentation will be webcast from the Southampton Inn in Southampton, New York.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at https://www.veracast.com/webcasts/bas/specpharma2010/id10116040.cfm.  A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.  

Alexza recently announced that it plans to advance AZ-007 (Staccato zaleplon) into Phase 2 clinical development with the first Phase 2 clinical trial projected to begin in 1H 2011.  AZ-007 is being developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients who awake in the middle of the night and have difficulty falling back asleep. For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
2. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
3. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
4. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
5. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
6. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Alexza Pharmaceuticals Files Shelf Registration Statement
9. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
10. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
11. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
(Date:2/4/2016)... WASHINGTON , Feb. 4, 2016  The ... Oversight and Government Reform Committee Chairman Jason ... (D-MD) for holding today,s hearing , "Developments ... drug price increases and growing questions about abusive ... Jason Chaffetz (R-UT) and Ranking Member Elijah ...
(Date:2/4/2016)... Feb. 4, 2016  Montoya Love is recognized by ... field of Pharmaceuticals. Montoya is the Regulatory Systems Operations ... Manufacturing and selling a ... Dickinson provides healthcare institutions, clinical laboratories and life ... countries across the globe. ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... ... , ... The American public tends to feel uncomfortable about drinking recycled waste ... or well water. The recent experience with lead contaminated water in Flint, Michigan, according ... toward increasing public acceptance of recycled waste water as drinking water. , The ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. ... announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. ... range of oral health care, including general dentistry, cosmetic treatments, periodontics, implant ...
Breaking Medicine News(10 mins):